2022 UW Dermatology SID Presentations & Abstracts

Several faculty, trainees and researchers representing UW Dermatology will be presenting their research at the upcoming SID Annual Meeting in Portland, Oregon from May 18-21, 2022.

Check out the full list of presentations and abstracts representing the Division of Dermatology below, or visit the SID Annual Meeting website for a full schedule of presenters.

Each year, the Society for Investigative Dermatology (SID)’s Annual Meeting invites a diverse group of researchers and clinicians, as well as hundreds of clinical trainees including residents, to exchange information on the latest advances in dermatology. The opportunity to interact with scientists who possess complementary knowledge, and present cutting-edge therapies has produced countless productive collaborations. In addition to the direct scientific goals, elements of the meeting are designed for the training and career development of young investigators. 

2022 SID Presentations

Thursday, May 19, 2022

9:21 AM - 9:33 AM

Abstract #427: The autophagy receptor TEX264 initiatesendoplasmic reticulum degradation in differentiating epidermal keratinocytes

• Concurrent Mini-Symposium 2, Epidermal Structure and Barrier Function

• Presenters: C. Simpson, C. Johnson
• Location: Oregon Ballroom 204 

9:21 AM - 9:33 AM

Abstract #825: Assessment of a circulating tumor DNA test for detecting recurrence of Merkel cell carcinoma

• Concurrent Mini-Symposium 5, Translational Studies
• T. Akaike, L. E. Gunnell, C. Doolittle-Amieva, K. Lachance, E. Hall, P. Nghiem
• Location: C123-C124

9:45 AM – 9:57 AM

LB1044 Inhibitors of CDK4/6 and HIF2a induce immunogenic cell death in merkel cell carcinoma cells 

• Concurrent Mini-Symposium 6, Late-Breaking Abstracts
• J. H. Lee, J. Lee, T. Pulliam, A. Berndt, C. Church, K. Lachance, S. Y. Park, P. Nghiem
• Location: Oregon Ballroom 201-202

10:09 AM - 10:21 AM

Abstract #201: What is the risk of Merkel cell carcinomarecurrence beyond pathologically clear margins? An analysis of 926 cases

• Concurrent Mini-Symposium 1, Clinical Research – Epidemiology and Observational Research
• A. Fu, K. Lachance, D. Hippe, P. Nghiem, S. Y. Park
• Location: Oregon Ballroom 203

Friday, May 20, 2022

10:09 AM - 10:21 AM

Abstract #541: Characterization of myeloid cell subsets in the tumor microenvironment of merkel cell carcinoma

• Concurrent Mini-Symposium 9, Innate Immunity, Microbiology, and Microbiome
• S. Tabachnick-Cherny, T. Pulliam, P. Nghiem
• Location: A105-A106

5:54 PM - 6:00 PM

Abstract #826: Recurrence risk in seropositive merkel cell carcinoma: A web-based calculator to interpret merkel cell polyomavirus antibody test results

• E-Poster Session 2 – Translational Studies
• L. E. Gunnell, K. Lachance, D. Hippe, M. Bierma, K. Cahill, T. Akaike, P. Nghiem
• Location: Terminal #5-Room B112

Saturday, May 21, 2022

10:21 AM - 10:33 AM

Abstract #292: Is it safe to discontinue immunotherapy after a response in merkel cell carcinoma?

• Concurrent Mini-Symposium 15, Clinical Research – Interventional Research
• L. Tachiki, L. Zawacki, Y. Moshiri, N. Alexander, T. Akaike, C. Doolittle-Amieva, T. Pulliam, S. Bhatia, P. Nghiem
• Location: A105-A106

2022 Abstracts

Abstract #159: Diagnostic overlap of drug-induced acute interstitial nephritis with cutaneous involvement and drug-induced hypersensitivity syndrome.

• Clinical Research-Epidemiology and Observational Research

• S. M. Collier, S. Ahuja, S. Briggs 

Abstract #166: Itch and skin inflammation at insulin pump sites in patients with type 1 diabetes

• Clinical Research-Epidemiology and Observational Research

• M. Shinohara, A. Kalus

Abstract #179: Merkel cell carcinoma recurrence risk is lower in patients with autoimmune disease than in those with other types of immune suppression

• Clinical Research-Epidemiology and Observational Research

• S. Y. Park, D. Hippe, L. Zawacki, M. Bierma, S. Bhatia, P. Nghiem, N. Singh

Abstract #247 : Type of immunosuppression matters: Efficacy of immunotherapy in immunosuppressed Merkel cell carcinoma patients

• Clinical Research-Epidemiology and Observational Research

• E. Gong, L. Zawacki, A. Remington, M. Bierma, K. Lachance, T. Akaike, P. Nghiem

Abstract #451: Modeling darier disease using gene-edited human keratinocytes and organotypic epidermis to identify therapeutic targets

• Genetic Disease, Gene Regulation, and Gene Therapy

• C. L. Simpson

Abstract #806: Histopathology features of cutaneous acute graft-versus-host disease can be reliably detected by noninvasive reflectance confocal microscopy

• Translational Studies
• M. Shinohara

Abstract #848: Inhibition of ATR augments immunogenicity in merkel cell carcinoma: A promising approach to address resistance to anti-PD-1 immunotherapy

• Translational Studies
• R. Bhakuni, P. Goff, J. H. Lee, T. Pulliam, S. Tabachnick-Cherny, C. D. Morningstar, P. Nghiem

LB879: Friend or foe? Identification of MCPyV-specific B cells in Merkel cell carcinomas suggests a functional role in tumor immunity

• Adaptive and Auto-Immunity
• H. J. Rodriguez Chevez, T. Pulliam2, A. Remington, P. Nghiem

LB1029: Correlation of merkel virus-specific CD8 T cells with response to immunotherapy in merkel cell carcinoma

• Translational Studies
• T. Pulliam, S. Jani, L. Jing, R. Kulikauskas, C. Church, D. Koelle, P. Nghiem